Showing results (241-250 of 365) with videos related to

Sort By:
Pageof 37
Breast Cancer Research and Treatment|October 24, 2018
Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in KoreaJai Min Ryu, Hee Jun Choi, Isaac Kim, et al.
Leukemia & Lymphoma|October 31, 2006
High incidence of mucosa-associated lymphoid tissue in primary thyroid lymphoma: a clinicopathologic study of 18 cases in the Korean populationJang Hyun Cho, Yeon Hee Park, Won Seog Kim, et al.
International Journal of Radiation Oncology, Biology, Physics|November 16, 2024
Significant Influence of Cardiac Radiation Dose on the Risk of Cardiotoxicity in Patients Receiving Adjuvant Trastuzumab and Radiation Therapy for Breast CancerTae Hoon Lee, Nalee Kim, Eun Kyoung Kim, et al.
Cancer Research and Treatment|May 16, 2024
A 10-Gene Signature to Predict the Prognosis of Early-Stage Triple-Negative Breast CancerChang Min Kim, Kyong Hwa Park, Yun Suk Yu, et al.
Future Oncology (London, England)|February 28, 2025
CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancerErika P Hamilton, Sibylle Loibl, Thomas Bachelot, et al.
Cancer Chemotherapy and Pharmacology|February 18, 2009
Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancerMyung Hee Chang, Kyoung Ha Kim, Hyun Jung Jun, et al.
Annals of Surgical Oncology|February 25, 2026
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 StudySherko Kuemmel, Peter A Fasching, Peter Schmid, et al.
Cell Reports. Medicine|June 7, 2025
Spatial and genomic profiling of residual breast cancer after neoadjuvant chemotherapy unveil divergent fates for each breast cancer subtypeEun Seop Seo, Sabin Park, Eun Yoon Cho, et al.
Investigational New Drugs|July 16, 2021
A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumorsBhumsuk Keam, Chan-Young Ock, Tae Min Kim, et al.
Oncology|June 7, 2014
Validation and comparison of CS-IHC4 scores with a nomogram to predict recurrence in hormone receptor-positive breast cancersYeon Hee Park, Seock-Ah Im, Eun Yoon Cho, et al.
Pageof 37